Celyad : La seconde vague en approche
>Une journée R&D en deux parties - Celyad organisait hier en fin d’après-midi sa journée R&D. Celle-ci avait pour but à la fois de faire un point sur les avancées cliniques en cours, et notamment CYAD-01 (avancées de l’étude THINK et DEPLETHINK), mais aussi de développer la seconde vague de recherche qui ne fait pas appel à l’édition du génome dans la synthèse du CAR-T. Malgré le lancement attendu de CYAD-02 en clinique courant 2020, seconde génération de CYAD-01 sous...Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.